Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(50.0%)
N/A
1(50.0%)
2Total
Phase 2(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04583904Completed

Prospective Evaluation of Novel Diagnostics for Tuberculosis in KwaZulu-Natal, South Africa

Role: collaborator

NCT01711099Not ApplicableUnknown

Efficacy of Extracorporeal Shockwave Myocardial Revascularization

Role: lead

NCT01584986Phase 2Completed

Autologous Angiogenic Cell Precursors (ACPs) for the Treatment of Peripheral Artery Disease

Role: lead

All 3 trials loaded